[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-330988-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-330988-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bill-analysis-report-california-assembly-bill-1906-cervical-cancer-screening-april-20-2026","Bill Analysis Report: California Assembly Bill 1906 Cervical Cancer Screening - April 20, 2026","","Analysis by the California Health Benefits Review Program (CHBRP) evaluates California Assembly Bill (AB) 1906 for 2025–2026 legislative consideration. The bill would require health insurance coverage without cost sharing for annual home test kits for cervical cancer screening when ordered by a health care provider. CHBRP estimates broad compliance for state-regulated plans, with no short-term public health impact. Medical evidence supports accurate hrHPV detection with properly collected self-samples. Costs are projected as premium increases, alongside utilization growth and potential long-term effects on screening access and disparities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bill-analysis-report-california-assembly-bill-1906-cervical-cancer-screening-april-20-2026/330988/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bill-analysis-report-california-assembly-bill-1906-cervical-cancer-screening-april-20-2026/330988.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What coverage requirement would AB 1906 create for cervical cancer screening at home?","Question",{"text":63,"@type":64},"AB 1906 would require coverage without cost sharing for annual home test kits for cervical cancer screening when referred by a health care provider.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which screening method does the CHBRP analysis primarily focus on for AB 1906?",{"text":68,"@type":64},"Because home test kits are designed to detect HPV rather than cervical cancer cells, CHBRP primarily focuses on hrHPV testing.",{"name":70,"@type":61,"acceptedAnswer":71},"What are CHBRP’s key findings on medical effectiveness and public health impact?",{"text":72,"@type":64},"Evidence cited by CHBRP indicates properly collected self-samples provide accurate, clinically valid hrHPV detection. CHBRP concludes passage would have no measurable short-term public health impact, while longer-term utilization may increase.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},330988,1790198498,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","A RE PORT TO THE 2 0 2 5–2026 CALIFORNIA LEGISLATURE  \nBill Analysis Report: California Assembly Bill 1906 Cervical Cancer  \nScreening  \nAPRIL 20 , 2026  \nCalifornia Health Benefits Review Program (CHBRP) University of California, Berkeley  \n[chbrp.org](chbrp.org)  \nKEY FINDINGS  \nAnalysis of California Assembly Bill 1906 Cervical Cancer Screening  \nSummary to the 2025–2026 California State Legislature, April 20, 2026  \nSummary  \nThe version of California Assembly Bill (AB) 1906 analyzed by the California Health Benefits Review Program (CHBRP) would require coverage without cost sharing for annual home test kits for cervical cancer screening as referred by a health care provider.  \nIf enacted, AB 1906 would apply to the health insurance of approximately 22,842,000 enrollees (60% of all Californians) .  \nBackground  \nCervical cancer develops in the cells of the cervix from persistent infection with high-risk human papillomavirus (hrHPV) . There are three primary methods for screening for cervical cancer: human papillomavirus (HPV) testing; cytology or Pap testing; and the HPV/Pap co-test. As currently available home test kits are designed to detect HPV rather than cervical cancer cells, CHBRP’s analysis of AB 1906 primarily focuses on hrHPV testing  \nHistorically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples, where a speculum or pelvic exam is not required. This can occur at home or in a health clinic or office, depending on the test used.  \nBenefit Coverage  \nAt baseline, 40% of enrollees in state-regulated health insurance have coverage without cost sharing for home test kits for cervical cancer screening. Postmandate, 100% of enrollees in state-regulated health insurance would have coverage compliant with AB 1906.  \nAB 1906 would not exceed essential health benefits (EHBs) .  \nMedical Effectiveness  \nThe Teal Wand is currently the only U.S. Food and Drug Administration (FDA)-authorized home test kit for  \ncervical cancer screening available for use (approved May 2025), demonstrating 95% agreement with clinician samples and strong sensitivity for high-grade dysplasia detection. The scientific consensus and pooled data, including the information reviewed for the United States Preventive Services Task Force ( USPSTF) guidelines that included studies comparing self-collected specimens, both in the home and in clinical settings, indicate very strong evidence that properly collected selfsamples provide accurate, stable, and clinically valid HPV detection suitable for future widespread homebased screening.  \nCost Impacts  \nPostmandate, CHBRP estimates that 6,798 enrollees would use cervical cancer screening home test kits, an increase of 5,753 new users of this modality as a result of AB 1906. For enrollees with baseline coverage without cost sharing, this increase in utilization is attributable to increased awareness. For enrollees without $0 baseline coverage, this increase in utilization is attributed to the removal of cost sharing and increased convenience of the home test option.  \nAB 1906 would increase premiums by $1,580,000 in the first year.  \nPublic Health Impacts  \nCHBRP concludes that passage of AB 1906 would have no measurable short-term public health impact.  \nLong-Term Impacts  \nOver time, utilization of home test kits for cervical cancer screening is expected to increase as provider familiarity grows, additional manufacturers enter the market, health plan outreach about the home test option expands, selfcollection technology advances, and home kits become more integrated into routine clinical workflows.  \nOver time, home test kits may address disparities in screening rates by reducing certain barriers to screening, including structural, individual, and cultural barriers.  \nCurrent as of April 20, 2026  [chbrp.org](chbrp.org)  \nAnal","cbCainHN38nXcyBX","https://ap.wps.com/l/cbCainHN38nXcyBX","pdf",922128,28,"English","# Acronyms and Terminology\n## Acronyms\n## Terminology\n# Overview: AB 1906 and Cervical Cancer Screening\n## Bill Language of AB 1906\n## What Is Cervical Cancer Screening?\n## How Effective Are FDA-Approved Home Test Kits for Cervical Cancer Screening?\n## Policy Context\n## Analytic Approach and Assumptions\n## Language Interpretation\n## Cost-Related Assumptions\n## AB 1906 Impacts","[{\"question\":\"What coverage requirement would AB 1906 create for cervical cancer screening at home?\",\"answer\":\"AB 1906 would require coverage without cost sharing for annual home test kits for cervical cancer screening when referred by a health care provider.\"},{\"question\":\"Which screening method does the CHBRP analysis primarily focus on for AB 1906?\",\"answer\":\"Because home test kits are designed to detect HPV rather than cervical cancer cells, CHBRP primarily focuses on hrHPV testing.\"},{\"question\":\"What are CHBRP’s key findings on medical effectiveness and public health impact?\",\"answer\":\"Evidence cited by CHBRP indicates properly collected self-samples provide accurate, clinically valid hrHPV detection. CHBRP concludes passage would have no measurable short-term public health impact, while longer-term utilization may increase.\"}]","Bill Analysis Report: California Assembly Bill 1906 Cervical Cancer Screening - April 20, 2026 | PDF",1789991001,71]